Regulators Promote Early Process Understanding As Key To Success In Cell Therapy Manufacturing
US and Canadian regulators espouse the need for early – and deep – knowledge of cell and gene therapy products as they progress through the pipeline to commercialization. Not doing so compromises product quality, and increases risks to patients.
